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Results twenty patients (mean 58.4 years) received len-
vatinib [12 mg (n = 7); 18 mg (n = 11); 24 mg (n = 2)] 
plus everolimus 5 mg. MtD was established as once daily 
lenvatinib 18 mg plus everolimus 5 mg. the most com-
mon treatment-related treatment-emergent adverse events 
(all dosing cohorts) were fatigue 60 % (grade ≥3: 10 %), 
mucosal inflammation 50 %, proteinuria (grade ≥3: 15 %), 
diarrhea (grade ≥3: 10 %), vomiting (grade ≥3: 5 %), 
hypertension, and nausea, each 40 %. In MtD and lowest-
dose cohorts (n = 18), best responses of partial response 
and stable disease were achieved in 6 (33 %) and 9 (50 %) 
patients, respectively.
Conclusions lenvatinib 18 mg combined with everolimus 
5 mg was associated with manageable toxicity consistent 
with individual agents and no new safety signals. Observed 
activity warrants further evaluation of the combination in 
advanced rCC patients.
Keywords lenvatinib · everolimus · Metastatic renal cell 
carcinoma · antitumor · mtOr · VegF
Introduction
Vascular endothelial growth factor (VegF)-mediated angi-
ogenesis and mammalian target of rapamycin (mtOr)-
mediated regulation of cell growth, cell proliferation, cel-
lular metabolism, and angiogenesis have been identified 
as key factors in the development of renal cell carcinoma 
(rCC) [1, 2]. Several agents that inhibit the VegF pathway 
have shown clinical benefit in metastatic rCC (mrCC), 
including sorafenib, sunitinib, axitinib, pazopanib, and bev-
acizumab (in combination with interferon-α) [3]. everoli-
mus and temsirolimus, both of which target the mtOr 
pathway, have also shown clinical benefit in mrCC [3]. 
Abstract 
Purpose lenvatinib is an oral multi-targeted tyrosine 
kinase inhibitor of VegFr1-3, FgFr1-4, PDgFrβ, ret, 
and KIt. everolimus is an oral mammalian target of rapa-
mycin inhibitor approved for advanced renal cell carcinoma 
(rCC). this phase 1b study assessed safety, maximum 
tolerated dose (MtD), and preliminary antitumor activity 
of lenvatinib plus everolimus in metastatic rCC (mrCC) 
patients.
Methods Patients with advanced unresectable or mrCC 
and eastern Cooperative Oncology group performance 
status 0–1 were eligible (number of prior treatments not 
restricted). Starting dose was lenvatinib 12 mg once daily 
with everolimus 5 mg once daily administered continu-
ously in 28-day cycles using a conventional 3 + 3 dose-
escalation design. at the MtD, additional patients were 
enrolled in an expansion cohort.
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In previously treated mrCC patients, everolimus demon-
strated partial response (Pr) rates of 1.8 %, with no com-
plete responses (Crs), and overall survival of 14.8 months 
[4]. although treatment with everolimus is considered a 
reference standard for previously treated rCC patients, as 
currently recommended by nCCn Clinical Practice guide-
lines in Oncology (nCCn guidelines®), tumor responses 
are generally low and transient in the majority of patients 
[5–7].
tumors are believed to become resistant to therapy 
through feedback mechanisms that compensate for targeted 
inhibition [1, 8]. Upregulation of hypoxia-inducible factor 1 
target genes, including VegF, has been implicated in rCC 
[9, 10]. additionally, genetic alterations leading to constitu-
tive activation of the mtOr signaling pathway have also 
been implicated in rCC [11, 12]. theoretically, a combina-
tion of agents targeting both VegF- and mtOr-mediated 
pathways could simultaneously block two critical signaling 
pathways activated in rCC and potentially overcome an 
aspect of resistance to single-agent therapy [13]. lenvatinib 
is an oral, multi-targeted tyrosine kinase inhibitor (tKI) 
of VegF receptors (VegFrs) 1-3, fibroblast growth fac-
tor receptors 1–4, platelet-derived growth factor receptor β, 
ret, and KIt [14]. In phase 1 and 2 studies, lenvatinib has 
demonstrated an acceptable toxicity profile and antitumor 
activity in patients with multiple solid tumors, including 
advanced rCC [15–19]. Data from in vitro binding assays 
show that lenvatinib binding specificity is mostly restricted 
to the receptor kinase domain of the kinome dendrogram 
[20]. the binding specificity of lenvatinib may be associ-
ated with less off-target toxicity, although this needs valida-
tion in clinical trials.
In a randomized, open-label, phase 1b/2 study, we evalu-
ated the use of everolimus in combination with lenvatinib 
in rCC patients with unresectable or metastatic disease 
(Clinicaltrials.gov: nCt01136733). the primary objec-
tives of the phase 1b component reported here were to 
determine the dose-limiting toxicities (Dlts), maximum 




Patients were aged ≥18 years, with histologically con-
firmed and documented evidence of unresectable advanced 
or mrCC and disease progression after prior therapy tar-
geting the VegF domain. two patients who had received 
no prior regimens were enrolled prior to a protocol 
amendment. eligible patients had an eastern Cooperative 
Oncology group performance status of 0 or 1, adequately 
controlled blood pressure, adequate hematologic, hepatic, 
renal, and blood coagulation function, and internationalized 
normalized ratio (Inr) of ≤1.5. there was no upper limit 
on prior therapies.
Key exclusion criteria included prior exposure to len-
vatinib, discontinuation of prior tKI due to toxicity, known 
intolerance to rapamycins, therapy with an anticancer 
agent or major surgery within 21 days, or treatment with 
any investigational agent within 30 days. Patients with sig-
nificant cardiovascular impairment, bleeding or thrombotic 
disorders requiring anticoagulant therapy and therapeutic 
Inr monitoring, prolongation of Qtc interval (>480 ms), 
untreated or unstable metastases to the central nervous sys-
tem, urine protein ≥1 g/24 h, uncontrolled diabetes [fasting 
glucose >1.5 × upper limit of normal (Uln)], fasting total 
cholesterol >7.75 mmol/l, and fasting triglyceride levels 
>2.5 × Uln were also excluded.
the study was approved by Institutional review 
Boards at each participating site and carried out in accord-
ance with local Independent ethics Committee standards, 
World Medical association Declaration of Helsinki, and 
the International Conference on Harmonisation of tech-
nical requirements for registration of Pharmaceuticals 
for Human Use guidelines. all patients provided written 
informed consent prior to participation.
Study design
this was the phase 1b component of a multicenter, open-
label, phase 1b/2 study. the phase 2 component of the 
study is ongoing. the study used a standard “3 + 3” dose-
escalation scheme. Patients were treated in sequential 
cohorts of escalating doses of lenvatinib in combination 
with everolimus, each administered once daily in 28-day 
treatment cycles until disease progression, development of 
unacceptable toxicity, or withdrawal of consent. the initial 
dose of lenvatinib was 12 mg once daily in combination 
with everolimus 5 mg once daily (Cohort 1). Subsequent 
doses were lenvatinib 18 mg once daily with everolimus 
5 mg once daily (Cohort 2) and lenvatinib 24 mg once daily 
with everolimus 5 mg once daily (Cohort 3).
Dlts were assessed during the first treatment cycle and 
were defined either as treatment-related failure to adminis-
ter ≥75 % of the planned dosage of lenvatinib/everolimus 
combination or as specific common toxicity criteria (CtC) 
grade ≥3 hematologic or nonhematologic toxicities con-
sidered to be at least possibly related to lenvatinib and/
or everolimus therapy. a treatment cycle was defined as 
28 days, and dosing was continuous. Hematologic toxici-
ties were defined as grade 4 neutropenia lasting at least 
7 days, febrile neutropenia with neutrophils <1 × 103/μl 
and a recorded temperature >38.5 °C, or grade ≥3 throm-
bocytopenia with bleeding or lasting more than 7 days. 
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nonhematologic toxicities were defined as grade 3 tox-
icities for >7 days (except grade 3/4 hyperamylasemia or 
hyperlipasemia without pancreatitis); in addition, nausea, 
vomiting, or diarrhea had to persist at grade 3 or 4 despite 
maximal medical therapy. If one of the first three patients 
enrolled within a cohort demonstrated a Dlt, an additional 
three patients were enrolled into that cohort. If two or 
more patients demonstrated Dlts during the first 4 weeks 
of therapy in any cohort, dose escalation was halted and, 
if necessary, additional patients were enrolled to the next 
lower dose to achieve a total of six patients in that cohort.
MtD was defined as the highest dose level resulting in 
≤1 of 6 Dlts. the definition of confirmed MtD was the 
highest dose level resulting in ≤1/3 of at least 10 patients 
experiencing Dlts during Cycle 1 or intolerable toxicities 
that could not be managed with dose interruption and/or 
reduction during Cycle 2. Once the MtD was established, 
the patient cohort at MtD was expanded and the MtD val-
idated by assessing Dlts during the first cycle and intoler-
able toxicities (i.e., not manageable with dose interruption 
and/or reduction) during the second cycle of therapy.
tumor measurements were assessed by clinical examina-
tion, computed tomography or magnetic resonance imaging, 
and bone scans and were based on investigator review data 
in conjunction with a radiologist using modified response 
evaluation Criteria in Solid tumors, version 1.1 [21].
tumor response assessments were conducted at baseline 
and then approximately every 8 weeks, and responses con-
firmed at a follow-up examination after ≥30 days. tumor 
response was defined as Cr, Pr, stable disease (SD) (min-
imum duration from randomization to SD ≥7 weeks), or 
progressive disease (PD). Disease control rate (DCr) was 
defined as the percentage of patients with a best overall 
response of Cr, Pr, or SD. Durable SD was defined as 
SD ≥23 weeks.
Statistical analysis
Cohorts of three to six patients each in phase 1b were con-
sidered adequate to evaluate initial safety assessments sup-
porting dose escalation. a minimum of 10 patients was 
considered adequate to confirm the MtD of phase 1b. the 
safety analysis set included all patients who received at 
least one dose of the study drug and have at least one post-
baseline safety evaluation and was the analysis set for all 
safety and efficacy evaluations.
Baseline and demographic variables, including age, gen-
der, and race, were summarized using descriptive statistics. 
Objective response rate (Orr), DCr, and durable SD rate 
were calculated with exact 95 % confidence intervals (CIs) 
using the Clopper and Pearson method. all statistical anal-




there were 20 patients recruited, dosed, and included in 
this analysis. Demographics and baseline characteristics 
for the study population are summarized in table 1. Mean 
age of patients was 58.4 years (standard deviation, 6.29), 
with the majority (90 %) being younger than 65 years. all 
patients were Caucasian, 70 % were male, and 85 % had 
received at least one prior anti-VegF therapy. the median 
number of prior therapeutic anticancer rCC regimens 
received was 1.5 (range 0–4).
Duration of treatment, dose-limiting toxicities, 
and maximum tolerated dose
Median overall duration of treatment (range) was 19.0 (1–
69) weeks across all dosing cohorts and was 32.0 (1–68), 
16.0 (1–69), and 3.5 (2–5) weeks for Cohorts 1, 2, and 3, 
respectively. Median number of treatment cycles was 5.5 
(range 1–18). treatment was discontinued for reasons other 
than disease progression by 30 % (6/20) of patients: one 
(14 %) patient in Cohort 1 for reason listed as “other—
clinical deterioration”; three (27 %) patients in Cohort 2 
[two patients due to adverse events (aes); one withdrew 
consent]; two (100 %) patients in Cohort 3 (one due to 
aes; one due to patient choice). lenvatinib doses were 
reduced in 10 patients (50 %) and treatment interrupted in 
14 patients (70 %). no patients required a dose reduction 
in everolimus; however, dose interruptions of everolimus 
were needed for nine patients. the lowest-dose cohort had 
the fewest number of lenvatinib dose reductions (Cohort 
1: 29 %; Cohort 2: 64 %; Cohort 3: 50 %); however, the 
number of patients with treatment interruption was compa-
rable in the three cohorts (Cohort 1: 71 %; Cohort 2: 73 %; 
Cohort 3: 50 %).
Four patients experienced Dlts: (1) CtC grade 3 
abdominal pain (Cohort 1; Dlt equivalent); (2) failure to 
administer >75 % of planned dose due to grade 3 elevated 
creatinine phosphokinase, grade 2 fatigue, and grade 1 
reflux (Cohort 2); (3) grade 3 nausea and vomiting (Cohort 
3; Dlt equivalent); and (4) failure to administer >75 % of 
planned dose due to grade 2 mucosal inflammation (Cohort 
3). Cohort 2, lenvatinib 18 mg once daily and everolimus 
5 mg once daily, was identified as the MtD.
Safety
twenty patients who received at least one dose of study 
therapy with ≥1 postbaseline safety evaluation were 
included in the safety population. treatment-emergent 
aes (teaes) occurred in 90 % (n = 18) of study patients, 
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although the majority of these aes were grade 1/2. grade 
3/4 aes were reported in 15 (75 %) patients. One patient 
experienced grade 5 cholangitis (Cohort 1) deemed unre-
lated to study medication and occurred 11 days after the 
last lenvatinib dose.
the most common treatment-related aes were fatigue 
(60 %), mucosal inflammation (50 %), diarrhea, hyper-
tension, nausea, proteinuria, and vomiting (40 % each) 
(table 2). the most common CtC grade ≥3 treatment-
related aes were hypertriglyceridemia (15 %), proteinuria 
(15 %), diarrhea, and fatigue (10 % each) (table 3). Hyper-
triglyceridemia and proteinuria occurred in 3/11 patients in 
Cohort 2 but was not present in Cohort 1 or 3.
tumor response
at the data cutoff date, Pr rate was 30 % (95 % CI 11.9–
54.3, n = 6; Cohort 1, n = 2; Cohort 2, n = 4) as assessed 
by investigators. no Crs were observed (table 4). In the 
MtD and lower-dose cohort, Pr was observed in 6/18 
patients (33 %) and SD or Pr was achieved in 15/18 
patients for a DCr of 83.3 % (table 4). Four patients expe-
rienced durable SD. the median progression-free survival 
(PFS) was 330 days (95 % CI 157–446; approximately 
10.9 months) at the MtD and lower-dose cohort, while the 
6- and 12-month PFS rates were 72.1 % (95 % CI 48.8–
95.4 %) and 49.5 % (95 % CI 22.7–76.2 %), respectively. 
a waterfall plot of maximum percent tumor change from 
baseline to postbaseline nadir is shown in Fig. 1. Figure 
2 illustrates a patient’s radiologic response to combined 
therapy.  
Discussion
therapeutic targeting of VegF- and mtOr-mediated path-
ways has expanded available treatment options for mrCC 
[3]. Several challenges remain to improving targeted 
treatment outcomes once resistance to initial single-agent 
therapy arises. Optimal sequencing of these agents has not 
been defined, and clinical development of combinations 
of agents has been challenging due to unacceptable toxic-
ity, complications of administration (e.g., combining oral 
and intravenous administration routes), or transient tumor 
responses. there is a continued need for more effective 
combinations of targeted agents, namely those associated 
with improved efficacy and manageable toxicity relative to 
single-agent sequential treatment [1, 3, 6].
the MtD and recommended phase 2 dose in this phase 
1b component was confirmed to be lenvatinib 18 mg once 
daily in combination with everolimus 5 mg once daily. all 
patients were previously treated with therapeutic regimens 
for rCC (with the exception of two patients with no prior 
treatment who were enrolled prior to a protocol amend-
ment). at the MtD and lower-dose cohort (lower-dose 
cohort: lenvatinib 12 mg plus everolimus 5 mg once daily), 
Table 1  Patient demographics and baseline characteristics
mTOR mammalian target of rapamycin, SD standard deviation, VEGF vascular endothelial growth factor
a
 therapeutic regimens for rCC
total  
(N = 20)
Cohort 1 Cohort 2 Cohort 3
lenvatinib 
12 mg + everolimus 
5 mg (n = 7)
lenvatinib 
18 mg + everolimus 
5 mg (n = 11)
lenvatinib 
24 mg + everolimus 
5 mg (n = 2)
age, year
 Mean (SD) 58.4 (6.29) 58.0 (3.92) 58.1 (7.97) 61.0 (2.83)
 Median 59.0 59.0 58.0 61.0
 Min, max 46, 72 53, 62 46, 72 59, 63
age group, n (%)
 <65 year 18 (90) 7 (100) 9 (82) 2 (100)
 ≥65 year 2 (10) 0 2 (18) 0
gender, n (%)
 Female 6 (30) 3 (43) 2 (18) 1 (50)
 Male 14 (70) 4 (57) 9 (82) 1 (50)
White, non-Hispanic, n (%) 20 (100) 7 (100) 11 (100) 2 (100)
number of prior anticancer regimens, median (range)a 1.5 (0–4) 3 (1–4) 1 (0–4) 0.5 (0–1)
Patients with prior anti-VegF treatment, n (%) 17 (85) 7 (100) 9 (82) 1 (50)
Patients with prior mtOr-targeted therapy, n (%) 7 (35) 4 (57) 3 (27) 0
Patients with both prior anti-VegF and mtOr- 
targeted therapy, n (%)
7 (35) 4 (57) 3 (27) 0
185Cancer Chemother Pharmacol (2014) 73:181–189 
1 3
the combination of lenvatinib and everolimus was associ-
ated with manageable toxicity. treatment-related aes were 
consistent with class effects typical of VegFr and mtOr 
inhibitors, with no new safety signals observed. the appar-
ent lack of additive toxicity from the combination may 
have important clinical implications as unexpected, and 
severe toxicities observed with other combined treatments 
have thus far limited clinical development of effective regi-
mens [22–24]. Fatigue, mucosal inflammation, proteinu-
ria, hypertension, as well as gastrointestinal (gI) toxicity 
(nausea, diarrhea, and vomiting) were the most common 
aes. Proteinuria, hypertriglyceridemia, diarrhea, and 
fatigue were the most common grade ≥3 treatment-related 
teaes.
a phase 1 study of everolimus plus sorafenib was con-
ducted in advanced mrCC patients [24]. While the Pr rate 
of 25 % was greater than typically observed with either 
drug as monotherapy, dose reductions (n = 3 of eight 
patients in one cohort) or study discontinuation (n = 2) 
was necessary for gI toxicity, and there was a substantially 
higher incidence of rash (55 vs. 29 % for everolimus alone, 
40 % for sorafenib alone) [24–26]. In a phase 2 trial com-
bining full doses of bevacizumab with everolimus, median 
PFS and Orr in previously untreated and previously 
treated patients were 9.1 and 7.1 months (30 and 23 %), 
respectively [27]. the combination regimen was associated 
with a toxicity profile consistent with the known toxicities 
of each single agent, prompting an attempt to study this 
combination in a phase 3 setting; however, the phase 3 
trial was closed prematurely due to failure of accrual. 
additional phase 2 trials in mrCC using combinations of 
bevacizumab and temsirolimus [28] or bevacizumab and 
everolimus [29] were associated with prohibitive toxic-
ity and low clinical activity to warrant consideration as a 
treatment regimen, which has raised serious questions as to 
whether targeted agents in rCC can be dosed fully together 
as combination treatment.
Whether the responses observed with the present com-
bination therapy confer an advantage relative to single-
agent therapy will require further study. In our exploratory 
analysis of tumor response, treatment at or below the MtD 
resulted in a Pr rate of 33.3 %, durable SD (≥23 weeks) 
rate of 22.2 %, and median PFS of approximately 
10.9 months in patients who received a median of 1.5 prior 
anti-VegF treatments. anti-VegFr multi-tKI treatments 
currently available for previously treated mrCC patients 
include sorafenib, sunitinib, axitinib, and pazopanib and 
have demonstrated response rates ranging between 9 and 
34 % and PFS between 4.7 and 8.3 months as single-agent 
treatment [30–34]. everolimus 10 mg once daily treat-
ment of patients with mrCC who had progressed on suni-
tinib, sorafenib, or both resulted in a Pr rate of 1.8 % and 
a median PFS of 4.9 months [4]. although data from dif-
ferent clinical trials must be interpreted with caution, the 
Table 2  treatment-related aes occurring in ≥20 % of patients (safety analysis set)
total (N = 20) Cohort 1 Cohort 2 Cohort 3
lenvatinib 12 mg +  
everolimus 5 mg (n = 7)
lenvatinib 18 mg +  
everolimus 5 mg (n = 11)
lenvatinib 24 mg + 
everolimus 5 mg 
(n = 2)
Patients with grades 1–5 aes, n (%) 18 (90) 7 (100) 9 (82) 2 (100)
grades 1–5 (≥20 %) aes by patient count, n (%)
 Fatigue 12 (60) 4 (57) 6 (55) 2 (100)
 Mucosal inflammation 10 (50) 3 (43) 5 (46) 2 (100)
 Diarrhea 8 (40) 3 (43) 4 (36) 1 (50)
 Hypertension 8 (40) 5 (71) 3 (27) 0
 nausea 8 (40) 4 (57) 3 (27) 1 (50)
 Proteinuria 8 (40) 3 (43) 5 (46) 0
 Vomiting 8 (40) 4 (57) 3 (27) 1 (50)
 Decreased appetite 7 (35) 2 (29) 4 (36) 1 (50)
 rash 7 (35) 2 (29) 4 (36) 1 (50)
 Constipation 5 (25) 2 (29) 2 (18) 1 (50)
 epistaxis 5 (25) 2 (29) 3 (27) 0
 Hypertriglyceridemia 5 (25) 0 5 (46) 0
 edema peripheral 5 (25) 1 (14) 4 (36) 0
 Dry skin 4 (20) 2 (29) 2 (18) 0
 Dyspnea 4 (20) 1 (14) 2 (18) 1 (50)
 Weight decreased 4 (20) 1 (14) 3 (27) 0
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Table 3  grade ≥3 treatment-related aes in safety analysis set
total (N = 20) Cohort 1 Cohort 2 Cohort 3
lenvatinib 12 mg +  
everolimus 5 mg  
(n = 7)
lenvatinib 18 mg +  
everolimus 5 mg  
(n = 11)
lenvatinib 24 mg + 
everolimus 5 mg 
(n = 2)
Patients with grade ≥3 aes, n (%) 14 (70) 5 (71) 8 (73) 1 (50)
Patients with grade 5 aes, n (%) 0 0 0 0
grade 3/4 aes by patient count, n (%)
 Hypertriglyceridemia 3 (15) 0 3 (27) 0
 Proteinuria 3 (15) 0 3 (27) 0
 Diarrhea 2 (10) 1 (14) 1 (9) 0
 Fatigue 2 (10) 1 (14) 1 (9) 0
 abdominal pain 1 (5) 1 (14) 0 0
 anemia 1 (5) 1 (14) 0 0
 Blood creatine phosphokinase ↑ 1 (5) 0 1 (9) 0
 Cardiomyopathy 1 (5) 0 1 (9) 0
 Cellulitis 1 (5) 0 1 (9) 0
 edema peripheral 1 (5) 1 (14) 0 0
 ejection fraction ↓ 1 (5) 0 1 (9) 0
 gastric hemorrhage 1 (5) 0 1 (9) 0
 gastritis 1 (5) 0 1 (9) 0
 Hypercholesterolemia 1 (5) 0 1 (9) 0
 Hyponatremia 1 (5) 0 1 (9) 0
 Hypophosphatemia 1 (5) 1 (14) 0 0
 lipase ↑ 1 (5) 0 1 (9) 0
 lung infection 1 (5) 0 1 (9) 0
 nausea 1 (5) 0 0 1 (50)
 Vomiting 1 (5) 0 0 1 (50)
 White blood cell count ↓ 1 (5) 0 1 (9) 0
Table 4  Best response
CI confidence interval, CR complete response, DCR disease control rate, PD progressive disease, PR partial response, SD stable disease
Objective response total (N = 20) Cohort 1 Cohort 2 Cohort 3
lenvatinib 12 mg +  
everolimus 5 mg  
(n = 7)
lenvatinib 18 mg +  
everolimus 5 mg  
(n = 11)
lenvatinib 24 mg + 
everolimus 5 mg 
(n = 2)
Pr, n (%) 6 (30.0) 2 (28.6) 4 (36.4) 0 (0.0)
95 % CI (11.9–54.3) (3.7–71.0) (10.9–69.2)
SD (≥7 weeks), n (%) 10 (50.0) 4 (57.1) 5 (45.5) 1 (50.0)
95 % CI (27.2–72.8) (18.4–90.1) (16.7–76.6) (1.3–98.7)
Durable SD rate (SD ≥ 23 weeks), n (%) 4 (20.0) 2 (28.6) 2 (18.2) 0 (0.0)
95 % CI (5.7–43.7) (3.7–71.0) (2.3–51.8)
PD, n (%) 1 (5.0) 0 (0.0) 1 (9.1) 0 (0.0)
DCr (Cr+Pr+SD), n (%) 16 (80.0) 6 (85.7) 9 (81.8) 1 (50.0)
95 % CI (56.3–94.3) (42.1–99.6) (48.2–97.7) (1.3–98.7)
Unknown, n (%) 3 (15.0) 1 (14.3) 1 (9.1) 1 (50.0)
95 % CI (3.2–37.9) (0.4–57.9) (0.2–41.3) (1.3–98.7)
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response rate of 33 % and PFS of 10.9 months for len-
vatinib in combination with everolimus are encouraging in 
the context of what has been reported in the literature.
In conclusion, the MtD and recommended phase 2 
dose was identified to be lenvatinib 18 mg once daily plus 
everolimus 5 mg once daily. Most treatment-related aes 
Fig. 1  Waterfall plot of percent 
of maximum change in summed 
longest diameter of target lesion 
from baseline, by investigator. 
PD progressive disease, PR par-
tial response, SD stable disease
SD 
PD SD SD SD SD SD SD SD SD SD 
PR 
PR PR PR 
PR PR 
Three additional patients could not be graphically represented because 






























Cohort 1: Lenvatinib 12 mg + everolimus 5 mg 
Cohort 2: Lenvatinib 18 mg + everolimus 5 mg 
Cohort 3: Lenvatinib 24 mg + everolimus 5 mg 
Fig. 2  radiologic response to lenvatinib in combination with everolimus. Baseline and follow-up images of one patient treated with lenvatinib 
14 mg and everolimus 5 mg
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were consistent with class effects typical of mtOr and 
VegFr inhibitors and were managed effectively by dose 
interruptions or reductions. Importantly, no new safety sig-
nals were evident with the use of combination therapy. the 
clinical benefit rate, including Prs and durable SD, appears 
favorable, and the ongoing phase 2 portion of this study 
will further elucidate the clinical value of this regimen.
Acknowledgments this work was supported by eisai Inc. the 
authors would like to thank Phase Five Communications Inc. for 
medical editorial assistance with this manuscript and C. andresen, 
former employee of eisai Inc., for medical monitoring. We also thank 
the commitment of participating patients, their families, and the study 
investigators for their invaluable contribution to this research.
Conflict of interest a.M. Molina has acted as a consultant and par-
ticipated in research for novartis, Inc. t.e. Hutson is a consultant and 
speaker bureau member for Pfizer, glaxoSmithKline, and novartis. 
J. larkin is a consultant for eisai Inc. a.M. gold, K. Wood, and D. 
Carter are employees of eisai ltd. r. Motzer is a consultant for aveo 
Oncology and Pfizer Oncology and received support for clinical trial 
conduct on behalf of Memorial Sloan-Kettering Cancer Center. M.D. 
Michaelson participated in research for eisai.
Open Access this article is distributed under the terms of the Crea-
tive Commons attribution license which permits any use, distribu-
tion, and reproduction in any medium, provided the original author(s) 
and the source are credited.
References
 1. rini BI, atkins MB (2009) resistance to targeted therapy in 
renal-cell carcinoma. lancet Oncol 10:992–1000. doi:10.1016/
S1470-2045(09)70240-2
 2. eichelberg C, Junker K, ljungberg B, Moch H (2009) Diagnostic 
and prognostic molecular markers for renal cell carcinoma: a crit-
ical appraisal of the current state of research and clinical applica-
bility. eur Urol 55:851–863. doi:10.1016/j.eururo.2009.01.003
 3. Hutson te (2011) targeted therapies for the treatment of meta-
static renal cell carcinoma: clinical evidence. Oncologist 16(suppl 
2):14–22. doi:10.1634/theoncologist.2011-S2-14
 4. Motzer rJ, escudier B, Oudard S, Hutson te, Porta C, Bracarda 
S, grünwald V, thompson Ja, Figlin ra, Hollaender n, Kay 
a, ravaud a, reCOrD-1 Study group (2010) Phase 3 trial of 
everolimus for metastatic renal cell carcinoma: final results and 
analysis of prognostic factors. Cancer 116:4256–4265. doi:10.10
02/cncr.25219
 5. nCCn Clinical Practice guidelines in Oncology (nCCn 
guidelines®) for Kidney Cancer, Version 1. (2013). http://
file3.baitianshi.com/upload/res/201212/c29/9f/5c8d5.pdf. 
accessed 20 Feb 2013
 6. Santos n, Wenger JB, Havre P, liu Y, Dagan r, Imanirad I, Ivey 
aM, Zlotecki ra, algood CB, gilbert SM, allegra CJ, Okunieff 
P, Vieweg J, Dang nH, luesch H, Dang lH (2011) Combination 
therapy for renal cell cancer: what are possible options? Oncol-
ogy 81:220–229. doi:10.1159/000333470
 7. Cho IC, Chung J (2012) Current status of targeted therapy for 
advanced renal cell carcinoma. Korean J Urol 53:217–228. doi:10
.4111/kju.2012.53.4.217
 8. gore Me, larkin JM (2011) Challenges and opportunities 
for converting renal cell carcinoma into a chronic disease with 
targeted therapies. Br J Cancer 104:399–406. doi:10.1038/sj.
bjc.6606084
 9. Kaelin Wg Jr (2005) the von Hippel-lindau protein, HIF 
hydroxylation, and oxygen sensing. Biochem Biophys res Com-
mun 338:627–638
 10. Staehler M, rohrmann K, Haseke n, Stief Cg, Siebels M (2005) 
targeted agents for the treatment of advanced renal cell carci-
noma. Curr Drug targets 6:835–846
 11. Brugarolas JB, Vazquez F, reddy a, Sellers Wr, Kaelin Wg Jr 
(2003) tSC2 regulates VegF through mtOr-dependent and 
-independent pathways. Cancer Cell 4:147–158
 12. thomas gV, tran C, Mellinghoff IK, Welsbie DS, Chan e, Fue-
ger B, Czernin J, Sawyers Cl (2006) Hypoxia-inducible factor 
determines sensitivity to inhibitors of mtOr in kidney cancer. 
nat Med 12:122–127
 13. Sosman Ja, Puzanov I, atkins MB (2007) Opportunities and 
obstacles to combination targeted therapy in renal cell cancer. 
Clin Cancer res 13(2 Pt 2):764s–769s
 14. Matsui J, Yamamoto Y, Funahashi Y, tsuruoka a, Watanabe 
t, Wakabayashi t, Uenaka t, asada M (2008) e7080, a novel 
inhibitor that targets multiple kinases, has potent antitumor 
activities against stem cell factor producing human small cell 
lung cancer H146, based on angiogenesis inhibition. Int J Cancer 
122:664–671
 15. Boss DS, glen H, Beijnen JH, Keesen M, Morrison r, tait B, 
Copalu W, Mazur a, Wanders J, O’Brien JP, Schellens JH, evans 
tr (2012) a phase I study of e7080, a multitargeted tyrosine 
kinase inhibitor, in patients with advanced solid tumours. Br J 
Cancer 106:1598–1604. doi:10.1038/bjc.2012.154
 16. Yamada K, Yamamoto n, Yamada Y, nokihara H, Fujiwara Y, 
Hirata t, Koizumi F, nishio K, Koyama n, tamura t (2011) 
Phase I dose-escalation study and biomarker analysis of e7080 in 
patients with advanced solid tumors. Clin Cancer res 17:2528–
2537. doi:10.1158/1078-0432.CCr-10-2638
 17. Sherman SI, Jarzab B, Cabanillas Me, licitra lF, Pacini F, Mar-
tins r, robinson B, Ball D, McCaffrey J, Shah MH, Bodenner 
D, allison r, newbold K, elisei r, O’Brien JP, Schlumberger M 
(2011) a phase II trial of the multitargeted kinase inhibitor e7080 
in advanced radioiodine (raI)-refractory differentiated thyroid 
cancer (DtC). J Clin Oncol 29(suppl):abstract 5503
 18. Schlumberger M, Jarzab B, Cabanillas Me, robinson B, Pacini 
F, Ball DW, McCaffrey JC, newbold K, allison r, Martins r, 
licitra lF, Shah MH, Bodenner D, elisei r, Burmeister la, 
Funahashi Y, Sellecchia r, andresen C, O’Brien JP, Sherman SI 
(2012) a phase II trial of the multitargeted kinase inhibitor len-
vatinib (e7080) in advanced medullary thyroid cancer (MtC). J 
Clin Oncol 30(suppl):abstract 5591
 19. Vergote I, teneriello M, Powell Ma, Miller DS, garcia aa, 
Mikheeva On, Pinter t, Bidzinski M, Cebotaru Cl, Fan J, ren 
M, Meneses n, Funahashi Y, Kadowaki t, O’Brien JP, Penson 
rt (2013) a phase II trial of lenvatinib in patients with advanced 
or recurrent endometrial cancer: angiopoietin-2 as a predictive 
marker for clinical outcomes. J Clin Oncol 31(suppl):abstract 
5520
 20. Fabian Ma, Biggs WH 3rd, treiber DK, atteridge Ce, azimio-
ara MD, Benedetti Mg, Carter ta, Ciceri P, edeen Pt, Floyd 
M, Ford JM, galvin M, gerlach Jl, grotzfeld rM, Herrgard S, 
Insko De, Insko Ma, lai ag, lélias JM, Mehta Sa, Milanov 
ZV, Velasco aM, Wodicka lM, Patel HK, Zarrinkar PP, lockhart 
DJ (2005) a small molecule-kinase interaction map for clinical 
kinase inhibitors. nat Biotechnol 23:329–336
 21. eisenhauer ea, therasse P, Bogaerts J, Schwartz lH, Sargent 
D, Ford r, Dancey J, arbuck S, gwyther S, Mooney M, rubin-
stein l, Shankar l, Dodd l, Kaplan r, lacombe D, Verweij J 
(2009) new response evaluation criteria in solid tumours: revised 
189Cancer Chemother Pharmacol (2014) 73:181–189 
1 3
reCISt guideline (version 1.1). eur J Cancer 45:228–247. 
doi:10.1016/j.ejca.2008.10.026
 22. Feldman Dr, Baum MS, ginsberg MS, Hassoun H, Flombaum 
CD, Velasco S, Fischer P, ronnen e, Ishill n, Patil S, Motzer 
rJ (2009) Phase I trial of bevacizumab plus escalated doses of 
sunitinib in patients with metastatic renal cell carcinoma. J Clin 
Oncol 27:1432–1439. doi:10.1200/JCO.2008.19.0108
 23. Sosman Ja, Flaherty Kt, atkins MB (2008) Updated results of 
phase I trial of sorafenib (S) and bevacizumab (B) in patients 
with metastatic renal cell cancer (mrCC). J Clin Oncol 
26(suppl):abstract 5011
 24. Harzstark al, Small eJ, Weinberg VK, Sun J, ryan CJ, lin aM, 
Fong l, Brocks Dr, rosenberg Je (2011) a phase 1 study of 
everolimus and sorafenib for metastatic clear cell renal cell carci-
noma. Cancer 117:4194–4200. doi:10.1002/cncr.25931
 25. afinitor [prescribing information]. east Hanover, nJ: novartis 
Pharmaceuticals Corp (2012)
 26. nexavar [prescribing information]. Wayne, nJ: Bayer HealthCare 
Pharmaceuticals Inc. (2012)
 27. Hainsworth JD, Spigel Dr, Burris Ha 3rd, Waterhouse D, Clark 
Bl, Whorf r (2010) Phase II trial of bevacizumab and everoli-
mus in patients with advanced renal cell carcinoma. J Clin Oncol 
28:2131–2136. doi:10.1200/JCO.2009.26.3152
 28. négrier S, gravis g, Pérol D, Chevreau C, Delva r, Bay JO, 
Blanc e, Ferlay C, geoffrois l, rolland F, legouffe e, Sevin 
e, laguerre B, escudier B (2011) temsirolimus and bevaci-
zumab, or sunitinib, or interferon alfa and bevacizumab for 
patients with advanced renal cell carcinoma (tOraVa): a ran-
domised phase 2 trial. lancet Oncol 12:673–680. doi:10.1016/
S1470-2045(11)70124-3
 29. Harshman lC, Barbeau S, McMillian a, Srinivas S (2013) a 
phase II study of bevacizumab and everolimus as treatment for 
refractory metastatic renal cell carcinoma. Clin genitourin Can-
cer 11:100–106. doi:10.1016/j.clgc.2012.12.002
 30. escudier B, eisen t, Stadler WM, Szczylik C, Oudard S, Sie-
bels M, negrier S, Chevreau C, Solska e, Desai aa, rolland F, 
Demkow t, Hutson te, gore M, Freeman S, Schwartz B, Shan 
M, Simantov r, Bukowski rM, target Study group (2007) 
Sorafenib in advanced clear-cell renal-cell carcinoma. n engl J 
Med 356:125–134
 31. Motzer rJ, rini BI, Bukowski rM, Curti BD, george DJ, Hudes 
gr, redman Bg, Margolin Ka, Merchan Jr, Wilding g, gins-
berg MS, Bacik J, Kim St, Baum CM, Michaelson MD (2006) 
Sunitinib in patients with metastatic renal cell carcinoma. JaMa 
295:2516–2524
 32. escudier B, eisen t, Stadler WM, Szczylik C, Oudard S, Stae-
hler M, negrier S, Chevreau C, Desai aa, rolland F, Demkow 
t, Hutson te, gore M, anderson S, Hofilena g, Shan M, Pena 
C, lathia C, Bukowski rM (2009) Sorafenib for treatment of 
renal cell carcinoma: final efficacy and safety results of the phase 
III treatment approaches in renal cancer global evaluation trial. J 
Clin Oncol 27:3312–3318. doi:10.1200/JCO.2008.19.5511
 33. Sternberg Cn, Davis ID, Mardiak J, Szczylik C, lee e, Wag-
staff J, Barrios CH, Salman P, gladkov Oa, Kavina a, Zarbá JJ, 
Chen M, McCann l, Pandite l, roychowdhury DF, Hawkins 
re (2010) Pazopanib in locally advanced or metastatic renal cell 
carcinoma: results of a randomized phase III trial. J Clin Oncol 
28:1061–1068. doi:10.1200/JCO.2009.23.9764
 34. rini BI, escudier B, tomczak P, Kaprin a, Szczylik C, Hutson 
te, Michaelson MD, gorbunova Va, gore Me, rusakov Ig, 
negrier S, Ou YC, Castellano D, lim HY, Uemura H, tarazi J, 
Cella D, Chen C, rosbrook B, Kim S, Motzer rJ (2011) Com-
parative effectiveness of axitinib versus sorafenib in advanced 
renal cell carcinoma (aXIS): a randomised phase 3 trial. lancet 
378:1931–1939. doi:10.1016/S0140-6736(11)61613-9
